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Despite its involvement in various immune functions, including the allogeneic activation
of T-lymphocytes, the relevance of calcium (Ca2+) for GVHD pathobiology is largely
unknown. To elucidate a potential association between Ca2+and GVHD, we analyzed
Ca2+-sensing G-protein coupled receptor 6a (GPRC6a) signaling in preclinical GVHD
models and conducted a prospective EBMT study on Ca2+ serum levels prior alloSCT
including 363 matched sibling allogeneic peripheral blood stem cell transplantations
(alloSCTs). In experimental models, we found decreased Gprc6a expression during
intestinal GVHD. GPRC6a deficient alloSCT recipients had higher clinical and
histopathological GVHD scores leading to increased mortality. As possible underlying
mechanism, we found increased antigen presentation potential in GPRC6a−/− alloSCT
recipients demonstrated by higher proliferation rates of T-lymphocytes. In patients
with low Ca2+ serum levels (≤median 2.2 mmol/l) before alloSCT, we found a higher
incidence of acute GVHD grades II-IV (HR = 2.3 Cl = 1.45–3.85 p = 0.0006), severe
acute GVHD grades III-IV (HR = 3.3 CI = 1.59–7.14, p = 0.002) and extensive chronic
GVHD (HR = 2.0 Cl = 1.04–3.85 p = 0.04). In conclusion, experimental and clinical data
suggest an association of reduced Ca2+ signaling with increased severity of GVHD.
Future areas of interest include the in depth analysis of involved molecular pathways
and the investigation of Ca2+ signaling as a therapeutic target during GVHD.
Keywords: graft-versus-host-disease, stem cell transplantation, calcium, GPRC6a, GVHD mouse models, EBMT
study
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INTRODUCTION
Calcium (Ca2+) signaling is involved in the regulation of
various immune functions, including B- and T-cell activation,
differentiation, T-lymphocyte-mediated cytotoxicity and
cytokine gene expression (1). It has been shown to modulate
the allogeneic activation of T-lymphocytes by antigen presenting
cells (2, 3) implicating a role for graft-versus-host disease
(GVHD) pathogenesis. Additionally, Ca2+ is known as
“danger-associated molecular pattern” (DAMP) and plays an
important role in the activation of T-cells, dendritic cells and
the multi-protein complex of the NOD-like receptor protein
(NLRP3) inflammasome (4). During conditioning prior to
allogeneic stem cell transplantation (alloSCT), with radiation
and/or chemotherapy, and later during GVHD increased
cell death of immune and tissue cells occurs. This increased
cell death can lead, among other things, to enhanced Ca2+
levels. A locally increased extracellular Ca2+ concentration
can induce the activation of the NLRP3 inflammasome via
the calcium sensing receptor and the G-protein coupled
receptor 6a (GPRC6a) (4). Several studies revealed a significant
role of DAMPs and the NLRP3 inflammasome in GVHD
morbidity and mortality (5–8). While NLRP3 function has
been studied in GVHD, upstream regulatory functions of
GPRC6a in GVHD remain to be elucidated. GPRC6a is
a class C, group 6, subtype A G-protein coupled receptor
which can be directly activated or positively modulated by
Ca2+ in concentrations above 5 mM; and was shown to be
involved in the regulation of inflammation, metabolism and
endocrine functions (9). In addition, GPRC6a was identified
in a genome-wide association study as a novel loci associated
with C-reactive protein levels, a general biomarker for systemic
inflammation (10).
The role of Ca2+ during GVHD is mostly unknown.
Thangavelu et al. showed an effect of genetically and inhibitor-
induced diminished intracellular Ca2+ levels on donor T-cell
survival during GVHD in preclinical models (11). Based on
prior knowledge and the fact that Ca2+ is a routine laboratory
parameter in patients undergoing alloSCT due to frequently
arising disturbances in calcium metabolism in these patients,
there is a strong rationale to study Ca2+ and its association
to GVHD. We performed experiments in preclinical GVHD
models using GPRC6A deficient mice; and the Transplant
Complications Working Party (TCWP) of the European Society
for Blood and Marrow Transplantation (EBMT) performed a
prospective, multicenter and non-interventional clinical study




Study Design and Statistics
Sample size for GVHD experiments was calculated by estimation
of time point–specific analyses based on the Student’s t-test
assuming 80% power and 0.05 2-sided level of significance.
Experiments with at least 5 animals per group (wildtype
transplanted [WT] and GPRC6a deficient transplanted
[GPRC6a−/−]) were performed 2 times. Animals were
randomized, including equal distribution of weight status and
mixed housing of different transplanted animals. For subsequent
analyses, transplant conditions were encoded. All experiments
were approved by the Regional Ethics Committee for Animal
Research (State Office of Health and Social Affairs, Berlin).
Survival data of at least 10 animals per group (WT and
GPRC6a−/− transplanted) were performed 2 times and analyzed
using the Kaplan-Meier method and compared with the Mantel-
Cox log-rank test. For all other data, the Student’s unpaired
t-test (two-tailed) was used if not indicated differently. Normality
tests and F test confirmed Gaussian distribution and equality
of variance between different groups. Values are presented as
mean ± standard deviation (SD). Values of P < 0.05 were
considered statistically significant. All statistical analyses were
performed using GraphPad Prism software (GraphPad Software
Inc, La Jolla, CA, United States).
Mice
Female C57BL/6 (B6) (H2b) and BALB/c (H2d) mice (10–
12 weeks old) were purchased from Charles River Laboratories
(Sulzfeld, Germany) and from Janvier (St. Berthevin Cedex,
France), respectively. Female GPRC6a deficient (GPRC6a−/−)
mice on B6 background were generated by Hans Bräuner-
Osborne, provided by Ulf Wagner (University Hospital Leipzig,
Germany) and were bred by and obtained from the central animal
unit of the Charité University Medicine. Mice had access to food
and water ad libitum.
GVHD Experiments
Our alloSCT acute GVHD models are characterized well (12–
16). We performed alloSCTs in the BALB/c→B6 model using
GPRC6a−/− mice as donors and recipients. GPRC6a−/− or
B6→BALB/c: Recipient mice received 800 cGy total body
irradiation from a 137Cs source as a split dose with a 4-h
interval and were injected intravenously (i.v.) with 5 × 106 bone
marrow (BM) cells and 0.5 × 106 splenic T-cells. BALB/c→
GPRC6a−/− or B6: Recipient mice received 1200 cGy total body
irradiation from a 137Cs source as a split dose with a 4-h interval
and were injected i.v. with 0.75 × 107 BM cells and 1 × 106
splenic T-cells. BM was flushed from the tibia and femur, and
single-cell suspension was prepared in phosphate-buffered saline
(PBS)/2% fetal calf serum/1 mM EDTA by gently passing through
a 23-G needle and over a 70 µm cell strainer (BD Biosciences,
San Jose, CA, United States). Splenic T-cell suspension was
obtained using the Pan T-cell Isolation Kit II (Miltenyi Biotec,
Bergisch Gladbach, Germany). T-cell purity was analyzed by CD3
staining and FACS analysis. For Gpcr6a expression analysis, we
used the established chemotherapy-based minor mismatch model
LP/J→B6 as described in (16). Mice were individually scored
twice a week for 5 clinical parameters (posture, activity, fur, skin,
and weight loss) on a scale from 0 to 2. Clinical GVHD score
was assessed by summation of these parameters. Survival was
monitored daily.
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Quantitative Real-Time PCR
A total of 2 µg RNA from colon of syngeneic and allogeneic
transplanted mice at day + 15 after alloSCT and complementary
DNA, obtained using the RNeasy Mini Kit (Qiagen, Venlo,
Netherlands) and the QuantiTect Reverse Transcription Kit
(Qiagen) following the manufacturer’s instructions, were
amplified (50◦C, 2 min; 95◦C, 10 min; 49 cycles of 95◦C, 10 s;
60◦C, 1 min) on DNA Engine Opticon (Bio-Rad, Hercules, CA,
United States) using the TaqMan Gene Expression Master Mix
(Life Technologies) and GPRC6a primers and probe from BioTez
GmbH (Berlin, Germany). Data were analyzed with Opticon
Monitor 3.1 analysis software (Bio-Rad) and the comparative CT
Method (11CT Method).
Flow Cytometry
Single-cell suspensions of blood, BM, lymph nodes, spleen
and thymus were prepared. Lymph nodes, splenocytes and
thymocytes were passed through a 40-µm cell strainer.
Erythrocytes were lysed with ammonium chloride. Cells
were washed twice and stained for 20 min at 4◦C in
PBS/0.5 mM EDTA/0.5% BSA with the following rat mAbs
from BD Biosciences: anti-H2kd (SF1-1.1-FITC and PE), anti-
CD8a (53-6.7-APC), anti-Ly-6G and Ly6C/Gr1 (RB6-8C5-APC),
anti-CD45R/B220 (RA3-6B2-PerCP-Cy5.5), anti-CD25 (PC61-
PerCP-Cy5.5), anti-CD4 (RM4-5-PE-Cy7), anti-CD80 (16-10A1-
PE), anti-CD86 (GL1-PerCP-Cy5.5), anti-CD11c (HL3-PE-Cy7),
anti-CD3e (145-2C11-APC-Cy7) and anti-CD11b (M1/70-APC-
Cy7). For staining of regulatory T-cells, Anti-Mouse/Rat FoxP3
Staining Set APC (eBioscience, San Diego, CA, United States)
was used following the manufacturer’s instructions. Samples were
analyzed by BD FACS Canto II (BD Biosciences) and FlowJo 7.6.5
Software (TreeStar Inc., Ashland, OR, United States).
Mixed Leukocyte Reaction
Dendritic cells were isolated from spleen of GPRC6a−/−
and B6 mice using a CD11c + isolation kit and splenic
T-cells from BALB/c mice were obtained using the mouse
Pan T-cell isolation Kit II (Miltenyi Biotec) according to
the manufacturer’s instructions. T-cells were loaded with
carboxyfluorescein diacetate succinimidylester (CFSE, Thermo
Fisher Scientific, Waltham, MA). 2.5 × 104 dendritic cells
(activators) and 2.5× 105 T-cell (responders) were incubated for
96 h at 37◦C and 5% CO2. Total cell counts being negative for
CFSE and positive for H2kd were analyzed via flow cytometry.
Proliferating cells were determined as cells, showing no CFSE
load compared to control samples without T-cell stimulation
at time point 0 h.
In vivo T-Cell Proliferation Assay
GPRC6a-/- and B6 recipients received 1200 cGy total body
irradiation from a 137Cs source. CD3 + lymphocytes were
isolated from spleens of BALB/c donors and enriched by Pan
T-Cell isolation kit (Milteny Biotec). 4 × 106 CFSE-loaded
CD3 + cells were injected i.v. into the tail vein. 72 h later,
mice were sacrificed and T-cells from spleen, thymus, blood and
lymph nodes were isolated and analyzed for proliferation by flow
cytometry. Total cell counts being negative for CFSE and positive
for H2kd were analyzed via flow cytometry. Proliferating cells
were determined as cells, showing no CFSE load compared to
control samples without T-cell stimulation at time point 0 h.
Clinical Data
Data Source, Study Design, and Data Collection
We asked EBMT centers performing more than 50 alloSCT
per year if they were willing to participate in this prospective
study. 17 centers in ten countries agreed to participate. Data
collection for the EBMT registry was approved by the IRB and/or
Ethics Committee in all centers. Data were prospectively collected
between 6/2014 and 3/2018. Consecutive alloSCT recipients with
acute leukemia, lymphoma or myelodysplastic syndrome (MDS)
receiving a first matched sibling alloSCT from peripheral blood,
regardless of conditioning, were eligible, provided they had
signed an informed consent document that permitted sharing of
clinical data according to national rules. Basic data on patient
and disease characteristics as well as longer term follow up was
taken from minimal essential data (MED-A) forms, which are
submitted from all consecutive patients to the central EBMT
registry. In addition, we designed registration and MED-B/C
forms that were prospectively collected and specific to this
study. The MED-B/C form contained detailed information on
calcium serum levels prior to alloSCT, patient characteristics,
infectious- as well as non-infectious complications, GVHD
staging, morbidity and mortality. Total Calcium (including
bound Ca2+ to proteins, mainly albumin, and anions; and free
ionized Ca2+) serum levels were determined photometrically and
corrected for albumin levels according to Payne’s formula [Ca corr
[mmol/L] = Ca measured [mmol/L] – [0.025× Albumin [g/L]+ 1]
at time of hospital admission for alloSCT directly before start
of conditioning therapy. Treatment teams completed the specific
forms at the time of registration and at day+ 100 after alloSCT.
Endpoints and Statistical Analyses
Patient, disease, and transplant-related characteristics for the two
cohorts [calcium serum levels prior to alloSCT above median
(>2.2 mmol/l)/calcium levels below median (<2.2 mmol/l)] were
compared by using χ2 statistics for categorical variables and the
Mann-Whitney test for continuous variables. Primary endpoint
was the incidence of acute GVHD. Secondary endpoints were
relapse incidence (RI), non-relapse mortality (NRM), overall
survival (OS), progression free survival (PFS) and the incidence
of chronic GVHD. PFS was defined as survival with no evidence
of relapse or progression. RI was defined as the probability
of having had a relapse during follow up time. Death without
experiencing a relapse was a competing event. NRM was defined
as death without evidence of relapse or progression. OS was
defined as the time from alloSCT to death, regardless of the cause.
Acute GVHD was graded according to the modified Seattle-
Glucksberg criteria (17) and chronic GVHD according to the
revised Seattle criteria (18). Cumulative incidence was used to
estimate the endpoints of NRM, RI, acute, and chronic GVHD
to accommodate for competing risks. To study acute and chronic
GVHD, we considered relapse and death to be competing events.
Probabilities of OS and PFS were calculated using the Kaplan–
Meier method. Univariate analyses were done using the Gray
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test for cumulative incidence functions and the log rank test
for OS and PFS. A Cox proportional hazards model was used
for multivariate regression. All variables differing significantly
between the 2 groups or factors associated with one outcome
in univariate analysis were included in the Cox model. The
following variables entered the multivariate models as possible
confounders: age, sex mismatch between recipient and donor,
diagnosis, disease status, Karnofsky score, number of CD34 cells
given, intensity of conditioning (EBMT definition: myeloablative
conditioning (MAC) was defined as TBI > 6 Gray or oral
busulfan > 8 mg/kg or intravenous busulfan > 6.4 mg/kg), type of
GVHD prophylaxis, ATG use, time from diagnosis to transplant,
year of transplant and CMV status. As the number of variables
was too high regarding the number of events, a stepwise selection
using Akaike information criterion (AIC) was run for all the
confounding factors. The difference between the two cohorts was
then assessed in the final selected model.
Results were expressed as the hazard ratio (HR) with the 95%
confidence interval (95% CI). Proportional hazards assumptions
were checked systematically for all proposed models using the
Grambsch-Therneau residual-based test. All tests were 2-sided.
The type I error rate was fixed at 0.05 for the determination
of factors associated with time-to-event outcomes. Statistical
analyses were performed in November 2018 with R 3.4.2 (R
Core Team (2017). R: A language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria1.
RESULTS
GPRC6a in Preclinical GVHD
In experimental acute GVHD, we found significantly decreased
Gprc6a expression levels in the colon of allogeneic transplanted
recipients at day + 15 after alloSCT (Figure 1A) during
established acute GVHD (Figures 1B,C); feasibly suggesting
defects in calcium induced signaling during acute GVHD.
No expression in skin and liver was detectable with the
available detection methods. Generally, diverse studies have
shown that GPRC6a is widely expressed albeit at relatively low
levels making detection challenging (9). To further analyze the
effect of GPRC6a on GVHD, we performed alloSCTs in the
BALB/c→B6 murine GVHD model using mice deficient for
GPRC6a (GPRC6a−/−, B6 background) either as recipients or
donors of alloSCT. In line with the expression data, GPRC6a−/−
alloSCT recipients exhibited higher GVHD morbidity and
mortality. GPRC6a−/− alloSCT recipients had significantly
increased weight loss (Figure 1D), GVHD scores (Figure 1E)
and mortality (Figure 1F). GVHD typical target organ damage
was also more pronounced in GPRC6a−/− alloSCT recipients,
exhibiting higher histopathological scores, significantly in liver
and non-significantly in colon, compared to wildtype (WT)
alloSCT recipients at day + 15 after alloSCT (Figure 1G).
The use of GPRC6a−/− as alloSCT donors did not result in
changed GVHD morbidity and mortality compared to WT
1https://www.R-project.org/
donors. Weight loss, GVHD scores and survival were similar in
both groups (Figures 1H–J). We conclude that GPRC6a signaling
in the alloSCT recipient but not in the alloSCT donor may play a
role during acute GVHD.
Inflammatory Cells in GPRC6a−/−
alloSCT Recipients
To elucidate the higher acute GVHD morbidity and mortality in
GPRC6a−/− alloSCT recipients, we analyzed peripheral blood,
spleen and axillary lymph nodes for inflammatory cells during
pronounced GVHD symptoms at day + 15 after alloSCT. In
GPRC6a−/− alloSCT recipients, we found significantly increased
CD4+ T-cells in blood and lymph nodes (Figures 2A,C). In
spleen, no significant changes compared to WT B6 alloSCT
recipients were detected (Figure 2B), however, in lymph nodes,
GPRC6a−/− alloSCT recipients exhibited significantly decreased
B-cell and dendritic cells and significantly increased granulocytes
and regulatory T-cells (Figure 2C). As underlying mechanism, we
found increased antigen presentation potential in GPRC6a−/−
alloSCT recipients demonstrated by higher proliferation rates
of T-lymphocytes. In mixed lymphocyte reaction, BALB/c
T-cells showed higher proliferation after 96 h incubation with
GPRC6a−/− dendritic cells as compared to WT dendritic cells
(Figure 3A). To analyze the proliferation potential of allogeneic
T-cells in vivo, we transplanted CFSE-labeled BALB/c (H2kd)
T-cells in either irradiated WT B6 or GPRC6a−/− mice (H2kb).
After 72 h, allogeneic T-cells in GPRC6a−/− mice showed a
significantly increased proliferation compared to WT B6 mice in
spleen and thymus (Figures 3B,C), a non-significant increase in
axillary lymph nodes (Figure 3D) and no significant changes in
the peripheral blood (Figure 3E).
We conclude that the potential to induce allogeneic T-cell
proliferation is increased in GPRC6a−/− antigen presenting
cells as compared to WT antigen presenting cells, providing a
possible mechanism for the observed increased acute GVHD in
GPRC6a−/− alloSCT recipients.
To further elucidate the clinical significance of these
preclinical findings showing a possible correlation between
Ca2+ and the occurrence of GVHD, we analyzed patient data
from a prospective, multicenter and non-interventional clinical
study performed by the Transplant Complications Working
Party of the EBMT.
Patients, Transplant Characteristics, and
Serum Calcium Measurement
The entry criteria for analysis of primary and secondary
endpoints were fulfilled in 363 patients. We used the last
total Ca2+ serum level that was measured in the individual
patients before start of conditioning. The Ca2+ cut off point
was determined at 2.2 mmol/l (median of measured total Ca2+
levels), resulting in a high (>median 2.2mmol/l) and a low
(≤median 2.2mmol/l) Ca2+ serum level group. Total Ca2+
serum levels were corrected for albumin levels; of note we found
in our population a strong correlation between calcium and
albumin values (r = 0.56, p < 0.0001). The main patients and
transplant characteristics that were included in the analysis of
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FIGURE 1 | GPRC6a in preclinical GVHD. (A) Reduced Gprc6a expression in colon of allogeneic (allo) compared to syngeneic (syn) transplanted mice during acute
GVHD at day + 15 after LP/J→B6 SCT (n = 10 per group). Gene expression level was normalized to Gapdh expression and is shown relative to gene level of a
reference naïve control. (B,C) GVHD Scores and survival in LP/J→B6 alloSCT. (D–G) GPRC6a deficient (−/−) mice as alloSCT recipients: BALB/c→GPRC6a−/−
alloSCT. GPRC6a−/− mice showed more GVHD-dependent weight loss (D), higher GVHD-Scores (E), decreased survival (F) (n = 20 per group) and higher
histopathological GVHD Scoring determined on HE sections of colon and liver at day + 15 after alloSCT (G) (n = 6 per group). B6 wildtype (WT) recipient mice served
as control. (H–J) GPRC6a−/− mice as alloSCT donors: GPRC6a−/−→BALB/c alloSCT. BALB/c recipients (n = 10) transplanted from GPRC6a−/− donor mice
showed no differences in weight loss (H), GVHD Score (I) and survival (J) compared to BALB/c recipients (n = 5) transplanted from B6 WT donor mice. In panels F
and J, P values were calculated by using the log-rank test. Error bars indicate mean ± SD. *P < 0.05; **P < 0.01; by Student’s t-test (two-tailed). Mice experiments
were performed twice.
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FIGURE 2 | Inflammatory cells in GPRC6a−/− recipient alloSCT mice during GVHD. FACS analysis of CD3, CD4, CD8, B220, CD11b, CD11c, Gr1, CD25, FoxP3
was performed in peripheral blood (A), spleen (B) and axillary lymph nodes (C). Samples from BALB/c→GPRC6a−/− at day + 15 after alloSCT (n = 6). Wildtype
(WT) B6 recipient mice served as control (n = 5). Mice experiments were performed twice. Error bars indicate mean ± SD. *P < 0.05; **P < 0.01; n.s., not significant
by Student’s t-test (two-tailed).
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FIGURE 3 | Proliferation of allogeneic T-cells by GPRC6a−/− cells. (A) T-cell proliferation in vitro (Mixed lymphocyte reaction): Percentage of proliferated T-cells after
96 h incubation with dendritic cells analyzed via CFSE in flow cytometry. T-cells were isolated from BALB/c mice, dendritic cells from B6 wildtype (WT) and
GPRC6a−/− mice (n = 3 per group). (B–E) T-cell proliferation in vivo: 4 × 106 CFSE labeled T-cells from BALB/c mice (H2kd +) were transplanted in irradiated B6
WT and GPRC6a−/− mice (n = 4 per group). After 72 h, donor (H2kd +) T-cell proliferation was assessed via CFSE in flow cytometry in spleen (B), thymus (C),
axillary lymph nodes (D), and peripheral blood (E). Proliferating cells were determined as cells, showing no CFSE load compared to control samples without T-cell
stimulation at time point 0 h. Error bars indicate mean ± SD. P < 0.05; significant by Student’s t-test (two-tailed).
overall survival are described in Supplementary Table 1. The
majority of parameters were balanced between the two cohorts.
However, a higher percentage of patients in complete remission
(CR) was observed in the group of patients with Ca2+ above
median before alloSCT. The frequency of patients with reduced-
intensity conditioning (RIC) versus myeloablative conditioning
differed significantly between the high Ca2+ group and the
low Ca2+ group. Additionally, the high Ca2+ group showed
significantly less patients treated with ATG and a significantly
different Karnofsky score. Therefore subsequent multivariate
analysis included these variables.
Incidence of Acute and Chronic GVHD
In the present study, the incidence of acute GVHD grades II-
IV and grades III-IV in the whole population at 100 days were
25% and 11%, respectively. We found a higher incidence of acute
GVHD grades II-IV in univariate (p = 0.0024) and multivariate
(HR = 2.3 Cl = 1.45–3.85 p = 0.0006) analysis in patients with low
Ca2+ serum levels before alloSCT as compared to patients with
high Ca2+ serum levels (Figure 4A and Tables 1, 2). Accordingly,
we found significant higher frequency of severe acute GVHD
grades III-IV in univariate (p = 0.0012) and multivariate
(HR = 3.3 CI = 1.59–7.14, p = 0.002) analysis in patients with
low Ca2+ serum levels before alloSCT as compared to patients
with high Ca2+ serum levels (Figure 4B and Tables 1, 2). Detailed
numbers of aGVHD organ grades are available for 33% of patients
TABLE 1 | Univariate global comparison of acute GVHD shown at





Serum Calcium ≤ 2.2 mmol/l 32% (25–39) 16% (11–22)
Serum Calcium > 2.2 mmol/l 18% (13–24) 6% (3–10)
p-value P = 0.0024 P = 0.0012
with liver and skin aGVHD grades and 17% of patients with gut
aGVHD grades (Supplementary Table 2).
In the whole population, the incidence of chronic GVHD
at 1 year and 2 years was 26% and 39%, respectively. The
incidence of severe chronic GVHD at 1 year and 2 years
was 16% and 21%, respectively. Extensive chronic GVHD was
significantly increased in multivariate (HR = 2.0 Cl = 1.04–
3.85 p = 0.04) analysis in patients with low Ca2+ serum levels
before alloSCT as compared to patients with high Ca2+ serum
levels (Figures 5A,B and Table 2). However, we observed a trend
but no significant differences in overall incidence of chronic
GVHD between the two cohorts. As expected, the chronic GVHD
incidence was significantly lower in alloSCT recipients receiving
anti-T-cell globulin as part of the conditioning regimen (ATG,
HR = 0.25 CI = 0.13–0.5, p < 0.0001). NIH classification of
chronic GVHD was available for 14% of patients shown in
Supplementary Table 3.
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FIGURE 4 | Incidence of acute GVHD until 100 days after alloSCT according to Ca2+ serum levels prior to alloSCT. Acute GVHD incidence of grades II-IV (A) and
grades III-IV (B) was increased in patients with low Ca2+ levels (≤2.2 mmol/l, red line) as compared to patients with high Ca2+ levels (>2.2 mmol/l, blue line).
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TABLE 2 | Multivariate global comparison.
Calcium ≤ 2.2 mmol/l vs. >2.2 mmol/l HR 95% CI p-value
Overall survival 1,02 0,65 1,59 0.9443
Progression free survival 1,28 0,86 1,89 0.22
Relapse incidence 0,95 0,60 1,52 0.84
Non-relapse mortality 1,75 0,98 3,13 0.06
Chronic GVHD 1,52 0,98 2,38 0.06
Extensive chronic GVHD 2,0 1,04 3,85 0.04
Acute GVHD II-IV 2,33 1,45 3,85 0.0006
Acute GVHD III-IV 3,33 1,59 7,14 0.002
Survival Endpoints
The overall survival (OS) in the whole population at 1 year
was 72%. We observed no significant differences in the OS
and progression free survival (PFS) of alloSCT recipients with
low Ca2+ serum levels before alloSCT as compared to patients
with high Ca2+ serum levels (Table 2 and Supplementary
Table 4, OS univariate p = 0.16; OS multivariate HR = 1.02
Cl = 0.65–1.59 p = 0.94 and PFS univariate p = 0.12; PFS
multivariate HR = 1.28 Cl = 0.86–1.89 p = 0.22). However, non-
relapse mortality (NRM) was significantly increased in alloSCT
recipients with low Ca2+ levels prior to start of conditioning
in univariate analysis (Figure 6 and Supplementary Table 4,
p = 0.0247). The same trend (but not significant) was seen in
NRM multivariate analysis (Table 2, HR = 1.75 Cl = 0.98–3.13
p = 0.06). The causes of death in patients without relapse were
mainly due to infection. A descriptive analysis of the causes of
death is given in Supplementary Table 5.
Incidence of Relapse
No difference in the relapse incidence was detected between
alloSCT recipients with low and high Ca2+ levels (Table 2
and Supplementary Table 4, univariate p = 0.8408; multivariate
HR = 0.95, CI = 0.6–1.52, p = 0.84).
We conclude that low Ca2+ levels (below median of
2.2 mmol/l) prior to alloSCT are associated with increased
incidence of acute GVHD as well as extensive chronic GVHD.
DISCUSSION
Ca2+ signaling is involved in various biologic processes
relevant for patients after alloSCT, including inflammation,
anti-infectious immunity, anti-tumor effects, kidney diseases
and bone homeostasis. Although our current descriptive
experimental and clinical results exhibit some limitations and
lacks further mechanistic insights, it gives first insights in a
possible association between Ca2+ and the occurrence of GVHD,
deserving further investigations.
In animal experiments, GPRC6a−/− alloSCT recipients had
increased GVHD morbidity and mortality. GPRC6a, a G protein
coupled receptor, was previously found to be activated by
increased extracellular Ca2+ levels leading to an increase in
the intracellular Ca2+ concentration, triggering the activation
of i.a. the NLRP3 inflammasome and caspase-1, mediated
through the phosphatidyl inositol/Ca2+ pathway. Activation
of the NLRP3 inflammasome via DAMPs has already been
shown to be connected to GVHD severity (7, 19). In preclinical
models, inhibition of the NLRP3 inflammasome lead to improved
GVHD morbidity and delayed GVHD-induced mortality (5–
7). Interestingly, when using NLRP3 deficient mice, this effect
was only prominent when deficiency was present in alloSCT
recipients, not in donors (6). In patients, recipient single
nucleotide polymorphisms of NLRP3 were found connected
to the incidence of acute GVHD grades 2–4 (20). While the
role of NLRP3 was studied in GVHD, potential upstream
immune regulatory functions of GPRC6a are unknown. Results
in GPRC6a−/− mice showing reduced inflammatory response
and reduced inflammasome activation in a mouse model
of carrageenan-induced footpad swelling (4), suggested that
GPRC6a deficiency may also lead to reduced GVHD-associated
inflammation as seen in GVHD studies analyzing the NLRP3
inflammasome. However, our data contradicts these findings,
as GPRC6a deficiency in alloSCT recipients was associated to
increased acute GVHD. As GPRC6a is located upstream from
the NLRP3 inflammasome, influence on other pathways is likely,
potentially leading to differing results. In addition, GPRC6a is
widely expressed throughout the body and can recognize multiple
ligands next to Ca2+, e.g., L-α-amino acids as L-arginine or
L-lysin, zinc, testosterone or osteocalcin acting as positive or
negative allosteric modulators (9, 21). The wide tissue expression
and multiple activators of GPRC6a, let assume a wide range
of functions and the entire scope of GPRC6a functions is
not yet known. In line, experimental data from GPRC6a−/−
mice show a diversity in physiological and pathophysiological
functions, mainly involving a role in inflammation, endocrine
functions and metabolism. However, functional phenotyping of
these mice is enclosed by disparities, e.g., in glucose and fat
or bone metabolism (9, 22). Whereas one group found glucose
intolerance and insulin resistance as well as osteopenia and
impaired osteoblast mediated bone formation in GPRC6a−/−
mice (22), other groups could not detect such phenotypes
(23, 24). This underlines the possibility that besides the Ca2+
mediated GPRC6a signaling, other signaling pathways contribute
to the observed phenotype in our GVHD model.
Of note, despite its regulatory functions in inflammation,
GPRC6a was shown to mediate the non-genomic effects of
testosterone and other steroids in vitro and in mice (25).
This raises the possibility that steroid therapy used for GVHD
prophylaxis may be influenced by GPRC6a expression.
GPRC6a can be directly activated by Ca2+ in concentrations
above 5 mM (9); and Ca2+ was shown to be involved in various
immune functions, including T-cell effector and regulatory
functions (1) as well as the allo-activation of T-lymphocytes by
antigen presenting cells (2, 3). In GPRC6a−/− mice, we also
found increased antigen presentation potential demonstrated
by higher proliferation rates of allogeneic T-lymphocytes
in GPRC6a−/− compared to wildtype alloSCT recipients,
leading to increased GVHD severity. Phenotypic differences of
GPR6CA−/− dendritic cells were detected concerning reduced
CD80 expression; however, further changes in costimulatory
molecules are likely and need further investigation. The role
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FIGURE 5 | Incidence of chronic GVHD until 12 months after alloSCT according to Ca2+ serum levels prior to alloSCT. Incidence of chronic GVHD (A) and extensive
chronic GVHD (B) was increased in patients with low Ca2+ levels (≤2.2 mmol/l, red line) as compared to patients with high Ca2+ levels (>2.2 mmol/l, blue line).
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FIGURE 6 | Non-relapse mortality (NRM) until 12 months after alloSCT according to Ca2+ serum levels prior to alloSCT. NRM was increased in patients with low
Ca2+ levels (≤2.2 mmol/l, red line) as compared to patients with high Ca2+ levels (> 2.2 mmol/l, blue line).
of Ca2+ signaling during GVHD is mostly unknown, although
first results in preclinical GVHD models support our data that
Ca2+ may play a role in mediating GVHD pathophysiology
(3, 11). However, Ca2+ signaling appears to remain complex,
multi-targetable and divergent and deserves further investigation.
E.g., the deletion of the plasma membrane proteins ORAI1 + 2
forming release-activated Ca2+ channels leads to the abolishment
of store-operated Ca2+ entry and a decrease of intracellular
Ca2+, and protects mice from allo-immunity in models of colitis
and GVHD (3). Contrasting and more coherent to our data,
the inhibition of inositol 1,4,5-trisphosphate 3-kinase B (Itpkb),
a negative regulator of Ca2+ influx, leads to an increase of
intracellular Ca2+ in donor T cells, protecting mice from acute
and chronic GVHD while maintaining a graft-versus-tumor-
effect (11). Interestingly, high calcium containing solutions are
effective to reduce mucositis after alloSCT raising the possibility
that Ca2+ signaling is involved in tissue repair or tissue
protection (26).
Our performed prospective study suggests an association of
Ca2+ with the occurrence of GVHD as low Ca2+ serum levels
(below median of 2.2 mmol/l) prior to alloSCT were found
to be a risk factor for the incidence of acute GVHD and for
extensive chronic GVHD. However, a limitation of this clinical
study is the lack of Ca2+ serum levels after alloSCT, e.g., during
occurrence of GVHD; leading to an incomplete understanding of
the effects of Ca2+ on post alloSCT immunity. The aim of our
prospective trial was to identify biomarkers that can be measured
before alloSCT. Therefore, no biomarker measurement at time
of GVHD onset was planned in the trial design. Importantly,
further investigations addressing the longitudinal progress of
Ca2+ levels post alloSCT will further shed light on the association
of Ca2+ and GVHD pathophysiology. In this study, we assessed
total Ca2+ in serum corrected to albumin levels, as approximate
45% of circulating Ca2+ is bound to proteins, mainly albumin,
which displays besides its high-capacity carrier role also several
physiological functions. Despite this correction, subsequent
analyses may address if free ionized Ca2+ and/or Ca2+ bound
to proteins or anions show an impact on GVHD incidence. Of
note, we found in our population a strong correlation between
calcium and albumin values (r = 0.56, p < 0.0001). Recently,
hypoalbuminemia was shown to predict worse NRM and inferior
OS (27) as well as severity of aGVHD (28) in alloSCT recipients.
Our patient population was restricted to alloSCT from
HLA-identical sibling donors, allowing to draw conclusions
from a homogeneous population with similar GVHD
prophylaxis strategies and similar incidences of GVHD and
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other complications. However, this includes the limitation that
we are therefore unable to draw definite conclusions from
these results regarding the association of Ca2+ serum levels
with outcome in matched unrelated donor alloSCT or in
haploidentical alloSCT, which are increasingly used. The herein
presented data can stimulate further research to perform analyses
of Ca2+ serum levels in other multiple cohorts allowing to widen
conclusions to other donor types.
CONCLUSION
This study gives first insights in a possible association of Ca2+
with the incidence and severity of GVHD. Future perspectives
of our results will include the clinical implementation of
risk-adapted GVHD prophylaxis strategies taking into account
calcium levels before alloSCT. Future studies can address the
question how the high risk of GVHD in the subpopulation
identified in this study can be reduced. A possible trial design
would be to test intensified GVHD prophylaxis regimens in
a randomized trial, based on calcium levels. This intensified
regimen could be the addition of a third immunosuppressive
drug in addition to the standard regimens consisting of
a calcineurin inhibitor and an antimetabolite. Furthermore,
future research areas of interest include: 1) to further analyze
the involved mechanistic and molecular pathways of Ca2+-
dependent allo-activation, and 2) to test if Ca2+ signaling
can serve as a therapeutic target during GVHD or other
inflammatory diseases.
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